Tokyo Tape
Sign in
← Alfresa Holdings

Quarterly report · Q1

2784.TEDINET S100OYAV
Period2022-04-01 → 2022-06-30
Filed2022-08-12
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 31
MetricValuePeriodScopeSource row
Revenue¥657.1bn2022-04-01 → 2022-06-30Cons.Net sales
Revenue¥2.59T2021-04-01 → 2022-03-31Cons.Net sales (5-year summary)
Revenue¥643.6bn2021-04-01 → 2021-06-30Cons.Net sales
Operating income¥3.1bn2022-04-01 → 2022-06-30Cons.Operating income
Operating income¥3.8bn2021-04-01 → 2021-06-30Cons.Operating income
Ordinary income¥3.7bn2022-04-01 → 2022-06-30Cons.Ordinary income
Ordinary income¥32.6bn2021-04-01 → 2022-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥4.7bn2021-04-01 → 2021-06-30Cons.Ordinary income
Profit before tax¥3.6bn2022-04-01 → 2022-06-30Cons.Income before income taxes
Profit before tax¥4.6bn2021-04-01 → 2021-06-30Cons.Income before income taxes
Net income (owners)¥2.1bn2022-04-01 → 2022-06-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥32.2bn2021-04-01 → 2022-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥3.2bn2021-04-01 → 2021-06-30Cons.Profit loss attributable to owners of parent
Net income¥2.2bn2022-04-01 → 2022-06-30Cons.Profit loss
Net income¥3.2bn2021-04-01 → 2021-06-30Cons.Profit loss
Total assets¥1.33Tat 2022-06-30Cons.Assets
Total assets¥1.30Tat 2022-03-31Cons.Assets
Total assets¥1.34Tat 2021-06-30Cons.Total assets (5-year summary)
Total liabilities¥852.5bnat 2022-06-30Cons.Liabilities
Total liabilities¥832.2bnat 2022-03-31Cons.Liabilities
Net assets / equity¥475.5bnat 2022-06-30Cons.Net assets
Net assets / equity¥471.8bnat 2022-03-31Cons.Net assets
Net assets / equity¥486.2bnat 2021-06-30Cons.Net assets (5-year summary)
Cash and deposits¥178.2bnat 2022-06-30Cons.Cash and deposits
Cash and deposits¥180.4bnat 2022-03-31Cons.Cash and deposits
EPS (basic)¥10.52022-04-01 → 2022-06-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥153.572021-04-01 → 2022-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥15.322021-04-01 → 2021-06-30Cons.Basic earnings loss per share (5-year summary)
Equity ratio35.8%at 2022-06-30Cons.Equity to asset ratio (5-year summary)
Equity ratio36.2%at 2022-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio36.3%at 2021-06-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 44
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-06-30−¥7.7bn
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-06-30−¥7.7bn
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-06-30¥82m
jpcrp040300-q1r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segmentrevenue2022-04-01 → 2022-06-30¥585.4bn
jpcrp040300-q1r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segmentrevenue external2022-04-01 → 2022-06-30¥580.9bn
jpcrp040300-q1r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥4.5bn
jpcrp040300-q1r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segmentsegment profit2022-04-01 → 2022-06-30¥2.4bn
jpcrp040300-q1r_E02962-000Manufacturing Businessreportable segmentrevenue2022-04-01 → 2022-06-30¥11.0bn
jpcrp040300-q1r_E02962-000Manufacturing Businessreportable segmentrevenue external2022-04-01 → 2022-06-30¥7.9bn
jpcrp040300-q1r_E02962-000Manufacturing Businessreportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥3.1bn
jpcrp040300-q1r_E02962-000Manufacturing Businessreportable segmentsegment profit2022-04-01 → 2022-06-30¥207m
jpcrp040300-q1r_E02962-000Medical Related Businessreportable segmentrevenue2022-04-01 → 2022-06-30¥8.8bn
jpcrp040300-q1r_E02962-000Medical Related Businessreportable segmentrevenue external2022-04-01 → 2022-06-30¥8.8bn
jpcrp040300-q1r_E02962-000Medical Related Businessreportable segmentsegment profit2022-04-01 → 2022-06-30−¥92m
jpcrp040300-q1r_E02962-000Self Medication Products Wholesaling Businessreportable segmentrevenue2022-04-01 → 2022-06-30¥59.6bn
jpcrp040300-q1r_E02962-000Self Medication Products Wholesaling Businessreportable segmentrevenue external2022-04-01 → 2022-06-30¥59.5bn
jpcrp040300-q1r_E02962-000Self Medication Products Wholesaling Businessreportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥142m
jpcrp040300-q1r_E02962-000Self Medication Products Wholesaling Businessreportable segmentsegment profit2022-04-01 → 2022-06-30¥448m
Total Of Reportable Segments And Otherssegment totalrevenue2022-04-01 → 2022-06-30¥664.9bn
Total Of Reportable Segments And Otherssegment totalrevenue external2022-04-01 → 2022-06-30¥657.1bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2022-04-01 → 2022-06-30¥7.7bn
Total Of Reportable Segments And Otherssegment totalsegment profit2022-04-01 → 2022-06-30¥3.0bn
Reconciling Itemsreconcilingrevenue2021-04-01 → 2021-06-30−¥7.1bn
Reconciling Itemsreconcilingrevenue intersegment2021-04-01 → 2021-06-30−¥7.1bn
Reconciling Itemsreconcilingsegment profit2021-04-01 → 2021-06-30¥126m
jpcrp040300-q1r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segmentrevenue2021-04-01 → 2021-06-30¥567.7bn
jpcrp040300-q1r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segmentrevenue external2021-04-01 → 2021-06-30¥563.5bn
jpcrp040300-q1r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segmentrevenue intersegment2021-04-01 → 2021-06-30¥4.2bn
jpcrp040300-q1r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segmentsegment profit2021-04-01 → 2021-06-30¥3.0bn
jpcrp040300-q1r_E02962-000Manufacturing Businessreportable segmentrevenue2021-04-01 → 2021-06-30¥11.1bn
jpcrp040300-q1r_E02962-000Manufacturing Businessreportable segmentrevenue external2021-04-01 → 2021-06-30¥8.2bn
jpcrp040300-q1r_E02962-000Manufacturing Businessreportable segmentrevenue intersegment2021-04-01 → 2021-06-30¥2.8bn
jpcrp040300-q1r_E02962-000Manufacturing Businessreportable segmentsegment profit2021-04-01 → 2021-06-30¥534m
jpcrp040300-q1r_E02962-000Medical Related Businessreportable segmentrevenue2021-04-01 → 2021-06-30¥8.4bn
jpcrp040300-q1r_E02962-000Medical Related Businessreportable segmentrevenue external2021-04-01 → 2021-06-30¥8.4bn
jpcrp040300-q1r_E02962-000Medical Related Businessreportable segmentsegment profit2021-04-01 → 2021-06-30−¥272m
jpcrp040300-q1r_E02962-000Self Medication Products Wholesaling Businessreportable segmentrevenue2021-04-01 → 2021-06-30¥63.6bn
jpcrp040300-q1r_E02962-000Self Medication Products Wholesaling Businessreportable segmentrevenue external2021-04-01 → 2021-06-30¥63.5bn
jpcrp040300-q1r_E02962-000Self Medication Products Wholesaling Businessreportable segmentrevenue intersegment2021-04-01 → 2021-06-30¥113m
jpcrp040300-q1r_E02962-000Self Medication Products Wholesaling Businessreportable segmentsegment profit2021-04-01 → 2021-06-30¥444m
Total Of Reportable Segments And Otherssegment totalrevenue2021-04-01 → 2021-06-30¥650.7bn
Total Of Reportable Segments And Otherssegment totalrevenue external2021-04-01 → 2021-06-30¥643.6bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2021-04-01 → 2021-06-30¥7.1bn
Total Of Reportable Segments And Otherssegment totalsegment profit2021-04-01 → 2021-06-30¥3.7bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 376
ItemContextValueUnit
Loss on valuation of investment securities elCurrentYTDDuration104000000JPY
Other elPrior1YTDDuration－JPY
Other elCurrentYTDDuration5000000JPY
Extraordinary lossPrior1YTDDuration133000000JPY
Extraordinary lossCurrentYTDDuration136000000JPY
Income before income taxesPrior1YTDDuration4602000000JPY
Income before income taxesCurrentYTDDuration3570000000JPY
Income taxes currentPrior1YTDDuration5797000000JPY
Income taxes currentCurrentYTDDuration5523000000JPY
Income taxes deferredPrior1YTDDuration-4439000000JPY
Income taxes deferredCurrentYTDDuration-4113000000JPY
Income taxesPrior1YTDDuration1358000000JPY
Income taxesCurrentYTDDuration1410000000JPY
Profit lossPrior1YTDDuration3244000000JPY
Profit lossCurrentYTDDuration2159000000JPY
Profit loss attributable to owners of parentPrior1YTDDuration3242000000JPY
Profit loss attributable to owners of parentCurrentYTDDuration2124000000JPY
Profit loss attributable to non controlling interestsPrior1YTDDuration2000000JPY
Profit loss attributable to non controlling interestsCurrentYTDDuration35000000JPY
Valuation difference on available for sale securities net of tax ociPrior1YTDDuration-1296000000JPY
Valuation difference on available for sale securities net of tax ociCurrentYTDDuration7023000000JPY
Deferred gains or losses on hedges net of tax ociPrior1YTDDuration0JPY
Deferred gains or losses on hedges net of tax ociCurrentYTDDuration-0JPY
Foreign currency translation adjustment net of tax ociPrior1YTDDuration54000000JPY
Foreign currency translation adjustment net of tax ociCurrentYTDDuration77000000JPY
Remeasurements of defined benefit plans net of tax ociPrior1YTDDuration-110000000JPY
Remeasurements of defined benefit plans net of tax ociCurrentYTDDuration-139000000JPY
Other comprehensive incomePrior1YTDDuration-1351000000JPY
Other comprehensive incomeCurrentYTDDuration6962000000JPY
Comprehensive incomePrior1YTDDuration1892000000JPY
Comprehensive incomeCurrentYTDDuration9122000000JPY
Comprehensive income attributable to owners of the parentPrior1YTDDuration1890000000JPY
Comprehensive income attributable to owners of the parentCurrentYTDDuration9087000000JPY
Comprehensive income attributable to non controlling interestsPrior1YTDDuration2000000JPY
Comprehensive income attributable to non controlling interestsCurrentYTDDuration35000000JPY
Revenues from external customersPrior1YTDDuration_jpcrp040300-q1r_E02962-000EthicalPharmaceuticalsWholesalingBusinessReportableSegmentsMember563524000000JPY
Revenues from external customersPrior1YTDDuration_jpcrp040300-q1r_E02962-000SelfMedicationProductsWholesalingBusinessReportableSegmentsMember63453000000JPY
Revenues from external customersPrior1YTDDuration_jpcrp040300-q1r_E02962-000ManufacturingBusinessReportableSegmentsMember8238000000JPY
Revenues from external customersPrior1YTDDuration_jpcrp040300-q1r_E02962-000MedicalRelatedBusinessReportableSegmentsMember8369000000JPY
Revenues from external customersPrior1YTDDuration_TotalOfReportableSegmentsAndOthersMember643586000000JPY
Revenues from external customersPrior1YTDDuration_ReconcilingItemsMember－JPY
Revenues from external customersPrior1YTDDuration643586000000JPY
Transactions with other segmentsPrior1YTDDuration_jpcrp040300-q1r_E02962-000EthicalPharmaceuticalsWholesalingBusinessReportableSegmentsMember4164000000JPY
Transactions with other segmentsPrior1YTDDuration_jpcrp040300-q1r_E02962-000SelfMedicationProductsWholesalingBusinessReportableSegmentsMember113000000JPY
Transactions with other segmentsPrior1YTDDuration_jpcrp040300-q1r_E02962-000ManufacturingBusinessReportableSegmentsMember2839000000JPY
Transactions with other segmentsPrior1YTDDuration_jpcrp040300-q1r_E02962-000MedicalRelatedBusinessReportableSegmentsMember－JPY
Transactions with other segmentsPrior1YTDDuration_TotalOfReportableSegmentsAndOthersMember7117000000JPY
Transactions with other segmentsPrior1YTDDuration_ReconcilingItemsMember-7117000000JPY
Transactions with other segmentsPrior1YTDDuration－JPY
Net salesPrior1YTDDuration_jpcrp040300-q1r_E02962-000EthicalPharmaceuticalsWholesalingBusinessReportableSegmentsMember567688000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2022-03-31pass
balance sheet identityconsolidated 2022-06-30pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2022-03-31pass
statement vs summary · net assetsconsolidated 2022-06-30pass
statement vs summary · net income attributable to parentconsolidated 2021-04-01/2021-06-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-06-30pass
statement vs summary · revenueconsolidated 2021-04-01/2021-06-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-06-30pass
statement vs summary · total assetsconsolidated 2022-03-31pass
statement vs summary · total assetsconsolidated 2022-06-30pass